Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 79, Issue 6, 1994, Pages 1693-1700xs

  Garnero, Patrick ^a   Shih, Weichung J ^b   Gineyts, Evelyne ^a   Karpf, David B ^b   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; COLLAGEN TYPE 1; PLACEBO; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN; COMPARATIVE STUDY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMAN; MIDDLE AGE; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; PREMENOPAUSE; SUPPORT, NON-U.S. GOV'T;

EID: 0028586042     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.79.6.7989477     Document Type: Article

References (48)

1. Melton III LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1227-1233.
2. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner WS. 1992 Axial bone density predicts fractures in older women. J Bone Miner Res. 7:633-638.
3. Seely DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. 1991 Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med. 115:837-842.
4. Johnston C, Slemenda CW, Melton III LJ. 1991 Clinical use of bone densitometry. N Engl J Med. 324:1105-1109.
5. Parfitt AM. 1988 Bone remodeling: relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures. In: Riggs BL, Melton III LJ, eds. Osteoporosis. New York: Raven Press; 45-94.
6. Delmas PD. 1988 Biochemical markers of bone turnover in osteoporosis. In: Riggs BL, Melton III LJ, eds. Osteoporosis. New York: Raven Press; 297-316.
7. Lips P, Courpron P. Meunier PJ. 1978 Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res. 26:13-17.
8. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M., Frame B, Rao DS. 1983 Relationship between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest. 72:13-96.
9. Eastell R, Delmas PD, Hodgson SF, Ericksen EF, Mann KG, Riggs BL. 1988 Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab. 67:741-748.
10. Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL. 1983 Increase in serum bone y-carboxyglutamic acid protein with aging in women. J Clin Invest. 71:1316-1321.
11. Stepan JJ, Pospichal J, Presi J, Pacovsky V. 1987 Bone loss and biochemical indices of bone remodeling in surgically postmenopausal women. Bone. 8:279-284.
12. Riggs BL, Jowsey J, Goldschmith RS, Kelly PJ, Hoffman DL, Arnaud CD. 1972 Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis. J Clin Invest. 51:1659-1663.
13. Lindsay R. 1988 Sex steroids in the pathogenesis and prevention of osteoporosis. In: Riggs BL, Melton III LJ, eds. Osteoporosis: etiology, diagnosis and management. New York: Raven Press; 333-358.
14. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. 1991 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross links. J Clin Endocrinol Metab. 72:367-373.
15. Reginster JY, Deroisy R, Denis D, et al. 1989 Prevention of postmenopausal bone loss by tiludronate. Lancet. 2:1469-1471.
16. Harris ST, Gertz BJ, Genant HK, et al. 1993 The effect of shortterm treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 76:1399-1406.
17. Santora AC, Bell NH, Chesnut CH, et al. 1993 Oral alendronate treatment of bone loss in postmenopausal osteopenic women [Abstract 58]. J Bone Miner Res. 8(SuppI 1):S131.
18. Garnero P, Delmas PD. 1993 Assessment of the serum levels of bone aklaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 77:1046-1053.
19. Garnero P, Grimaux M, Demiaux B, Préaudat C, Seguin P, Delmas PD. 1992 Measurement of serum osteocalcin with a human-specific two-site radioimmunoassay. J Bone Miner Res. 7:1389-1397.
20. Fujimoto D, Suzuki M, Uchiyama S, Miyamoto S, Inoue T. 1983 Analyses of pyridinoline cross-linking compound of collagen fibers in human urine. J Biochem (Tokyo). 94:1133-1136.
21. Eyre DR, Koob TJ, Van Neww KP. 1984 Quantitation of hydrox-ypyridinium cross-links in collagen by high performance liquid chromatography. Anal Biochem. 137:380-388.
22. Black D, Buncan A, Robins SP. 1989 Quantitative analysis of pyridinium cross-links of collagen in urine using ion-paired re-versed-phase high performance chromatography. Anal Biochem. 169:197-203.
23. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. 1990 Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic bone disease. Bone Miner. 8:87-96.
24. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ. 1991 Evaluation of urinary hydroxypyridinium cross-link measurements as resorption markers in metabolic bone disease. Eur J Clin Invest. 21:310-315.
25. Harvey RD, McHardy KC, Reid IW. 1991 Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab. 72:1189-1194.
26. Seyedin SM, Kung VT, Daniloff YN, et al. 1993 Immunoassay for urinary pyridinoline. The new marker of bone resorption. J Bone Miner Res. 8:635-641.
27. Hanson DA, Weis MAE, Bollen AM, Maslan SH, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked N-telopep-tides in urine. J Bone Miner Res. 7:1251-1258.
28. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type 1 collagen: a new marker of bone degradation. Clin Chem, 39:635-640.
29. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. 1993 Immunoassay of pyridinoline cross-link excretion in normal adults and in Paget's disease. J Bone Miner Res, 8:643-648.
30. Civitelli R, Gonelli S, Sacchei F, et al. 1988 Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest, 82:1268-1274.
31. Christiansen C, Overgaard K, Riis BJ. 1990 The ophmum regimens for usage of intranasal salmon calcitonin and treatment of postmenopausal osteoporosis. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Third International Symposium on Osteoporosis, Copenhagen, Denmark. 3:1888-1891.
32. Johansen JS, Riis BJ, Delmas PD, Christiansen C. 1987 Plasma BGP: an indicator of spontaneous bone loss, the effect of estrogen treatment in postmenopausal women. Eur J Clin Invest. 18:191-195.
33. Garnero P, Grimaux M, Seguin P, Delmas PD. 1994 Characterization of immunoreachve forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res, 9:255-264.
34. Melkko J, Niemi S, Risteli L, Risteli J. 1990 Radioimmunoassay of the carboxy terminal propeptide of human type 1 collagen. Clin Chem. 36:1328-1332.
35. Eriksen EF. 1986 Normal and pathological remodeling of human trabecular bone: three dimensional reconstrucHon of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev. 7:379-408.
36. Delmas PD, Schelemmer A, Gineyts E, Riis B, Christiansen C. 1991 Urinary excretion of pyridinoline cross-links correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.J Bone Miner Res. 6:639-644.
37. Podenphant J, Johansen JS, Thomsen K, Riis BJ, Leth A, Christiansen C. 1987 Bone turnover in spinal osteoporosis. J Bone Miner Res. 2:497-503.
38. Delmas PD, Wilson DM, Mann KG, Riggs BL. 1983 Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab, 57:1028-1030.
39. Hassager C, Fabbri-Mabelli G, Christiansen C. 1993 The effect of the menopause and hormone replacement therapy on serum car-boxyterminal propeptide of type 1 collagen. Osteoporos Int. 3:50-52.
40. Ebeling PR, Peterson JM, Riggs BL. 1992 Utility of type 1 procollagen assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res. 7:1243-1250.
41. Smedsrod B, Melko J, Risteli L, Risteli J. 1990 Circulating C-terminal propeptide of type 1 procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem], 271:345-350.
42. Hassager C, Jensen LT, Risteli L, Risteli J, Christiansen C. 1993 Serum carboxy-terminal pyridinoline cross-linked telopeptide of type 1 collagen (slCTP) as a marker of bone metabolism: the effect of menopause, hormone replacement therapy, and anabolic steroid. J Bone Miner Res. 8(Suppl 1):S249.
43. Kelly PJ, Pocockk NA, Sambrook PN, Eisman JA. 1989 Age and menopause-related changes in indices of bone turnover. J Clin Endocrinol Metab. 69:1160-1165.
44. Garnero P, Sornay-Rendu E, Delmas PD. 1994 Assessment of age-related changes of bone turnover in normal women with new biochemical markers. J Bone Miner Res, 9(Suppl 1):S389.
45. Parfitt AM. 1982 The coupling of bone formation to resorption: a critical analysis of the concept and its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res. 4:1-6.
46. Balena R, Toolan BC, Shea M, el al. 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariecto-mized nonhuman primates. J Clin Invest. 92:2577-2586.
47. Hasling C, Ericksen EF, Melkko J, et al. 1991 Effects of combined estrogen-gestogen regimen on serum levels of the carboxy-terminal propeptide of human type 1 procollagen in osteoporosis. J Bone Miner Res. 12:1295-1300.
48. Rosen HN, Dresner-Pollak R, Moses AC, et al. 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as markers of bone turnover in humans. Calcif Tissue Int. 54:26-29.